Jazz Pharmaceuticals/JAZZ

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Ticker

JAZZ

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Dublin, Ireland

Employees

2,800

JAZZ Metrics

BasicAdvanced
$6.6B
Market cap
20.86
P/E ratio
$5.04
EPS
0.62
Beta
-
Dividend rate
$6.6B
0.62
2.266
1.62
139.627
156.004
2.10%
4.07%
9.41%
20.86
1.72
1.79
-2.02
6.66
2.81%
-302.92%
16.41%
-17.81%

What the Analysts think about JAZZ

Analyst Ratings

Majority rating from 18 analysts.
Buy

JAZZ Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1.61% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$902M
-10.87%
Net income
-$15M
-115.52%
Profit margin
-1.61%
-117.33%

JAZZ Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 35.88%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$4.51
$4.84
$5.02
$2.68
-
Expected
$4.43
$4.93
$5.18
$4.18
$4.74
Surprise
1.76%
-1.87%
-3.17%
-35.88%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Jazz Pharmaceuticals stock?

Jazz Pharmaceuticals (JAZZ) has a market cap of $6.6B as of July 04, 2024.

What is the P/E ratio for Jazz Pharmaceuticals stock?

The price to earnings (P/E) ratio for Jazz Pharmaceuticals (JAZZ) stock is 20.86 as of July 04, 2024.

Does Jazz Pharmaceuticals stock pay dividends?

No, Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Jazz Pharmaceuticals dividend payment date?

Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders.

What is the beta indicator for Jazz Pharmaceuticals?

Jazz Pharmaceuticals (JAZZ) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Jazz Pharmaceuticals stock

Buy or sell Jazz Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing